Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA warns Juul over marketing practices

Written by: | no-reply@reuters.com | Dated: Monday, September 9th, 2019

 

FDA warns Juul over its marketing practices

 

(Reuters) – The U.S. Food and Drug Administration said on Monday it had issued a warning letter to Juul Labs Inc over its marketing practices for e-cigarettes, the latest in the agency’s efforts to curb the use of the devices that have become extremely popular among teens.

The agency said Juul’s labeling and advertising of its vaping devices can lead to consumers believing that the products present a lower risk of tobacco-related diseases or are less harmful than other commercially marketed tobacco products. (bit.ly/2krQlGX)

Juul did not immediately respond to Reuters request for comment.

Juul has already come under scrutiny for its marketing efforts, including its use of social media influencers to promote its vaping devices, with the Federal Trade Commission launching an investigation last month.

The FDA said it was concerned that Juul’s representation of products may look like switching to its vaping device was a safer alternative to cigarettes.

Juul uses a nicotine concentration of 5% in its products, which could potentially increase their addictiveness, and nicotine salts that are used to mask the harshness of nicotine, the agency said questioning their usage.

The FDA has also asked Juul to provide a written response within 15 days outlining its plan to correct its violations and to provide requested documents and information within 30 days of the date of the letter.

Last year, the agency had requested documents from Juul to examine the high rates of youth use and had conducted a surprise inspection at Juul’s San Francisco headquarter and seized documents.

 

Reporting by Manojna Maddipatla and Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli

 

Reuters source:

https://www.reuters.com/article/us-juul-fda-ecigarettes/fda-warns-juul-over-its-marketing-practices-idUSKCN1VU1OC

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom